#news

The Iranian Blood Transfusion Organization (IBTO) and its most recent activities are featured on TIF’S website.

As large parts of the world prepare for a second wave of coronavirus cases governments have pinned their hopes on the rapid development of a vaccine to provide a route…

Our August 2020 newsletter has just been published! Read about our latest updates, including country activities, international projects, educational updates for patients with thalassaemia and haemoglobin disorders, and our novel…

AstraZeneca Plc and the University of Oxford have resumed the British clinical trials of its Covid-19 vaccine, after the initial suspension over concerns with a participant who fell ill. University…

The latest news from TIF’s Member ”Thalassemics India” in one place! In this issue you will find all the information on the new Thalassaemia Screening & Counselling Center in New…

AstraZeneca Plc has begun final-stage, Phase III trial of its coronavirus vaccine AZD1222 in the U.S., according to the company´s latest statement. Trial centers across the US are recruiting up to 30,000 adults aged 18 years…

Malaysia needs more geneticists in order to identify thalassaemia patients at an early stage, stated Health Minister Datuk Seri Dr Adham Baba, after launching the 2019 Malaysia Thalassaemia Registry (MTR)…

TIF´s upcoming webinar on ”Iron Monitoring in Thalassaemia”, specially designed and launched for medical specialists and healthcare professionals with a particular interest in the field of haemoglobin disorders and thalassaemia,…

IMARA Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of haemoglobin, announced the U.S. Food and Drug…

Researchers around the world are racing to develop a vaccine against Covid-19, with more than 140 candidate vaccines now tracked by the World Health Organization (WHO). Vaccines normally require years of testing…